Admission blood lactate levels of patients diagnosed with cerebrovascular disease effects on short- and long-term mortality risk

ArticleAçık Erişim

Özet

Objective: Our study was carried out on patients admitted to the emergency ward with acute stroke symptoms that were subsequently diagnosed with cerebrovascular disease. We aimed to examine the relationship between these patients' admission lactate levels and their 1-, 3-, and 12-month mortality rates in order to evaluate the prognostic value of lactate levels. Methods: Our data were obtained retrospectively from 568 patients diagnosed with acute ischemic stroke at our emergency department between 1 January 2017 and 1 January 2018. Patient data were accessed via the hospital patient database. Included patients' files were assessed for examination and history taken at admission, comorbid diseases, demographic characteristics, treatments utilized, and laboratory results. Hyperlactatemia was defined as a lactate level of over 2 mmol/L. The relationship between lactate levels and survival was investigated. Patients' complication rates after discharge were assessed alongside their 1-, 3-, and 12-month mortality. Results: Our study assessed 568 patients. Out of these patients, 400 patients met our inclusion criteria and constituted the study population. These patients were separated into two groups according to their lactate levels. The hyperlactatemic group had a statistically significant increase in 1-, 3-, and 12-month mortality rates in comparison to the other group. Conclusions: Our study found that hyperlactatemia was associated with a higher risk of 1-, 3-, and 12-month mortality, suggesting that it has predictive prognostic value. In the future, we believe that prospective observational studies and/or large-scale retrospective studies will be of great value in providing more insight into this topic. © 2021 John Wiley & Sons Ltd.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13460Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1111/ijcp.14161Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorSakal, Cemalettin
dc.contributor.authorAk, Rohat
dc.contributor.authorTaşçı, Abdullah
dc.contributor.authorKırkpantur, Ecem Deniz
dc.contributor.authorÜnal Akoğlu, Ebru
dc.contributor.authorCimilli Ozturk, Tuba
dc.date.accessioned2026-10-18T20:28:17.412838348Z
dc.date.available2026-10-18T20:28:17.412838348Z
dc.date.issued2021
dc.description.abstractObjective: Our study was carried out on patients admitted to the emergency ward with acute stroke symptoms that were subsequently diagnosed with cerebrovascular disease. We aimed to examine the relationship between these patients' admission lactate levels and their 1-, 3-, and 12-month mortality rates in order to evaluate the prognostic value of lactate levels. Methods: Our data were obtained retrospectively from 568 patients diagnosed with acute ischemic stroke at our emergency department between 1 January 2017 and 1 January 2018. Patient data were accessed via the hospital patient database. Included patients' files were assessed for examination and history taken at admission, comorbid diseases, demographic characteristics, treatments utilized, and laboratory results. Hyperlactatemia was defined as a lactate level of over 2 mmol/L. The relationship between lactate levels and survival was investigated. Patients' complication rates after discharge were assessed alongside their 1-, 3-, and 12-month mortality. Results: Our study assessed 568 patients. Out of these patients, 400 patients met our inclusion criteria and constituted the study population. These patients were separated into two groups according to their lactate levels. The hyperlactatemic group had a statistically significant increase in 1-, 3-, and 12-month mortality rates in comparison to the other group. Conclusions: Our study found that hyperlactatemia was associated with a higher risk of 1-, 3-, and 12-month mortality, suggesting that it has predictive prognostic value. In the future, we believe that prospective observational studies and/or large-scale retrospective studies will be of great value in providing more insight into this topic. © 2021 John Wiley & Sons Ltd.
dc.identifier.doi10.1111/ijcp.14161
dc.identifier.issn1368-5031
dc.identifier.issue8
dc.identifier.pmid33759312
dc.identifier.scopus2-s2.0-85103423381
dc.identifier.startpagee14161
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13460
dc.identifier.volume75
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofInternational Journal of Clinical Practice
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBrain Ischemia
dc.subjectHospital Mortality
dc.subjectHumans
dc.subjectHyperlactatemia
dc.subjectLactic Acid
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectStroke
dc.subjectfibrinolytic agent
dc.subjectadult
dc.subjectaged
dc.subjectarea under the curve
dc.subjectArticle
dc.subjectclinical examination
dc.subjectcomorbidity
dc.subjectdemography
dc.subjectemergency ward
dc.subjectfemale
dc.subjecthealth care utilization
dc.subjecthospital admission
dc.subjecthospital discharge
dc.subjecthuman
dc.subjectischemic stroke
dc.subjectlaboratory test
dc.subjectlactate blood level
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical history
dc.subjectmedical record review
dc.subjectmiddle aged
dc.titleAdmission blood lactate levels of patients diagnosed with cerebrovascular disease effects on short- and long-term mortality risk
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus15
rdl.source.indexSCOPUS